Voyager Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

VYGR$1.99+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)


· · March 31, · · December 31,
· 2025 · 2024
Assets · · · · ·
Current assets:
Cash and cash equivalents	$74,755	$71,367
Marketable securities	161,264	195,317
Accounts receivable	1,623	1,504
Related party collaboration receivable (see note 8)	487	676
Prepaid expenses and other current assets	7,077	7,945
Total current assets	245,206	276,809
Property and equipment, net	13,929	14,314
Restricted cash	2,874	2,874
Marketable securities, non-current	59,103	65,704
Operating lease, right-of-use assets	32,128	33,349
Total assets	$353,240	$393,050
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,634	$3,996
Accrued expenses	9,053	14,171
Operating lease liabilities	7,430	7,227
Deferred revenue (see Note 8)	21,095	24,394
Total current liabilities	40,212	49,788
Operating lease liabilities, net of current portion	34,566	36,499
Deferred revenue, net of current portion	4,760	6,003
Other non-current liabilities	1,000	1,000
Total liabilities	80,538	93,290
Commitments and contingencies (see note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024	—	—
Common stock, $0.001 par value: 120,000,000 shares authorized at March 31, 2025 and December 31, 2024; 55,209,485 and 54,731,316 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	55	55
Additional paid-in capital	630,051	626,296
Accumulated other comprehensive loss	(199)	(407)
Accumulated deficit	(357,205)	(326,184)
Total stockholders’ equity	272,702	299,760
Total liabilities and stockholders’ equity	$353,240	$393,050

The accompanying notes are an integral part of these condensed consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.